🔎 Trials Near Me

Utama › Leukemia Limfositik Kronik › Texas › Houston

Kajian klinikal Leukemia Limfositik Kronik di Houston, TX

17 kajian untuk Leukemia Limfositik Kronik sedang mencari peserta di lokasi dalam dan sekitar Houston (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

Mengambil pesertaFasa 1
  • Houston Methodist Hospital, Houston
  • Texas Children's Hospital, Houston
Sehingga umur 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT01853631

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
  • UT MD Anderson Cancer Center, Houston
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Mengambil pesertaFasa 1/2
  • Research Site, Houston
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT06542250

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Mengambil pesertaFasa 1/2
  • Md Anderson Cancer Center, Houston
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05006716

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Mengambil pesertaFasa 3
  • Md Anderson Cancer Center, Houston
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06973187

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Mengambil pesertaFasa 3
  • The University of Texas MD Anderson Cancer Center, Houston
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT07648264

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Mengambil pesertaFasa 2
  • M D Anderson Cancer Center, Houston
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Sep 2026 · NCT04169737

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Mengambil pesertaFasa 1/2
  • Research Site, Houston
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06564038

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Mengambil pesertaFasa 1/2
  • MD Anderson, Houston
Umur 12 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT04588922

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Mengambil pesertaFasa 1/2
  • University of Texas MD Anderson Cancer Center, Houston
Umur 13 hingga 90 · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT06533579

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Mengambil pesertaFasa 2
  • MD Anderson Cancer Center, Houston
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Jul 2026 · NCT06967610

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Mengambil pesertaFasa 1
  • MD Anderson Cancer Center, Houston
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Jul 2026 · NCT05131022

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Mengambil pesertaFasa 1
  • MD Anderson Cancer Center, Houston
Umur 13 ke atas · Semua jantina · Dikemas kini 5 Mei 2026 · NCT04771572

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Mengambil pesertaFasa 1
  • MD Anderson Cancer Center, Houston
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Mac 2026 · NCT04830137

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Mengambil pesertaFasa 4
  • University of Texas MD Anderson Cancer Center, Houston
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Mac 2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Mengambil pesertaFasa 4
  • University of Texas MD Anderson Cancer Center, Houston
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Mac 2026 · NCT06876649

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Mengambil pesertaFasa 1
  • Oncology Consultants, Houston
  • University of Texas MD Anderson Cancer Center, Houston
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Dis 2025 · NCT05602363

Kajian Leukemia Limfositik Kronik di bandar lain

Kajian lain di Houston

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.